Pfizer Receivables 2010-2024 | PFE

Pfizer receivables for the quarter ending September 30, 2024 were $14.451B, a 30.35% increase year-over-year.

  • Pfizer receivables for 2023 were $11.177B, a 2.05% increase from 2022.
  • Pfizer receivables for 2022 were $10.952B, a 4.59% decline from 2021.
  • Pfizer receivables for 2021 were $11.479B, a 45.07% increase from 2020.

Pfizer Receivables 2010-2024 | PFE

  • Pfizer receivables for 2023 were $11.177B, a 2.05% increase from 2022.
  • Pfizer receivables for 2022 were $10.952B, a 4.59% decline from 2021.
  • Pfizer receivables for 2021 were $11.479B, a 45.07% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B